Banyan Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Banyan Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$1.52M	Sell	28,323 -34,488	-55%	-$1.83M	0.13%	181
2014 Q2	$3.29M	Sell	62,811 -7,407	-11%	-$379K	0.28%	98
2014 Q1	$3.71M	Sell	70,218 -9,354	-12%	-$432K	0.32%	83
2013 Q4	$3.19M	Sell	79,572 -17,195	-18%	-$677K	0.22%	100
2013 Q3	$3.66M	Buy	96,767 +21,190	+28%	+$827K	0.32%	77
2013 Q2	$2.96M	Buy	+75,577	New	+$2.94M	0.58%	60

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Banyan Partners's TEVA Position: Q3 2014 in Review

Banyan Partners reduced its Teva Pharmaceuticals (TEVA) stake by 55% in Q3 2014, selling an estimated $1.83M and leaving 28,323 shares worth $1.52M. The position accounts for 0.13% of the portfolio, ranked #181.

Banyan Partners first reported a position in TEVA in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.71M in Q1 2014. 772 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

Banyan Partners held 28,323 shares of Teva Pharmaceuticals worth $1.52M as of Q3 2014.
Banyan Partners sold 34,488 Teva Pharmaceuticals shares in Q3 2014, an estimated $1.83M.
Teva Pharmaceuticals made up 0.13% of Banyan Partners's portfolio in Q3 2014, its #181 holding.
Banyan Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
Banyan Partners's Teva Pharmaceuticals position peaked at $3.71M in Q1 2014.
772 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on Banyan Partners's 13F filing for Q3 2014, filed 14 Nov 2014.